|
1
|
Lee CR, Goldstein JA and Pieper JA:
Cytochrome P450 2C9 polymorphisms: A comprehensive review of the
in-vitro and human data. Pharmacogenetics. 12:251–263. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gerbal-Chaloin S, Pascussi JM,
Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrère N and
Maurel P: Induction of CYP2C genes in human hepatocytes in primary
culture. Drug Metab Dispos. 29:242–251. 2001.PubMed/NCBI
|
|
3
|
Andersson T, Holmberg J, Röhss K and Walan
A: Pharmacokinetics and effect on caffeine metabolism of the proton
pump inhibitors, omeprazole, lansoprazole and pantoprazole. Br J
Clin Pharmacol. 45:369–375. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gardiner SJ and Begg EJ: Pharmacogenetics,
drug-metabolizing enzymes, and clinical practice. Pharmacol Rev.
58:521–590. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Onof S, Hatanaka T, Miyazawa S, Tsutsui M,
Aoyama T, Gonzalez FJ and Satoh T: Human liver microsomal diazepam
metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6,
2C19 and the 3A subfamily. Xenobiotica. 26:1155–1166. 1996.
View Article : Google Scholar
|
|
6
|
Paveliu MS, Bengea S and Paveliu FS:
Individualized drug response related to genetic variations of
cytochrome P450 isoforms and other enzymes. Rev Farmacia.
58:245–254. 2010.
|
|
7
|
Adrian A, Daniela C, Axente GI, Ionut O,
Flavian R and Anamaria G: Detection of CYP2D6*6 allele by real time
polymerase chain reaction in Romanian population. Rev Farmacia.
58:353–361. 2010.
|
|
8
|
Goldstein JA: Clinical relevance of
genetic polymorphisms in the human CYP2C subfamily. Br J Clin
Pharmacol. 52:349–355. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang M, Tybring G, Dahl ML and Lindh JD:
Impact of cytochrome P450 2C19 polymorphisms on
citalopram/escitalopram exposure: A systematic review and
meta-analysis. Clin Pharmacokinet. 53:801–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Serrano D, Torrado S, Torrado-Santiago S
and Gisbert JP: The influence of CYP2C19 genetic polymorphism on
the pharmacokinetics/-pharmacodynamics of proton pump
inhibitor-containing Helicobacter pylori treatments. Curr Drug
Metab. 13:1303–1312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Myrand SP, Sekiguchi K, Man MZ, Lin X,
Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, et al:
Pharmacokinetics/genotype associations for major cytochrome P450
enzymes in native and first-and third-generation Japanese
populations: Comparison with Korean, Chinese and Caucasian
populations. Clin Pharmacol Ther. 84:347–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adamec C: Example of the use of the
nonparametric test. Test X2 for comparison of 2 independent
examples. Cesk Zdrav. 12:613–619. 1964.In Czech. PubMed/NCBI
|
|
13
|
Barrett JC, Fry B, Maller J and Daly MJ:
Haploview: Analysis and visualization of LD and haplotype maps.
Bioinformatics. 21:263–265. 2005. View Article : Google Scholar
|
|
14
|
Ng PC and Henikoff S: Accounting for human
polymorphisms predicted to affect protein function. Genome Res.
12:436–446. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meyer UA: Pharmacogenetics and adverse
drug reactions. Lancet. 356:1667–1671. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu
SN and Wang DM: Genetic polymorphism, linkage disequilibrium,
haplotype structure and novel allele analysis of CYP2C19 and CYP2D6
in Han Chinese. Pharmacogenomics J. 9:380–394. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He N, Yan FX, Huang SL, Wang W, Xiao ZS,
Liu ZQ and Zhou HH: CYP2C19 genotype and S-mephenytoin
4′-hydroxylation phenotype in a Chinese Dai population. Eur J Clin
Pharmacol. 58:15–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kimura M, Ieiri I, Mamiya K, Urae A and
Higuchi S: Genetic polymorphism of cytochrome P450s, CYP2C19, and
CYP2C9 in a Japanese population. Ther Drug Monit. 20:243–247. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roh HK, Dahl ML, Tybring G, Yamada H, Cha
YN and Bertilsson L: CYP2C19 genotype and phenotype determined by
omeprazole in a Korean population. Pharmacogenetics. 6:547–551.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamada S, Onda M, Kato S, Matsuda N,
Matsuhisa T, Yamada N, Miki M and Matsukura N: Genetic differences
in CYP2C19 single nucleotide polymorphisms among four Asian
populations. J Gastroenterol. 36:669–672. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang M, Dahl ML, Tybring G, Götharson E
and Bertilsson L: Use of omeprazole as a probe drug for CYP2C19
phenotype in Swedish Caucasians: Comparison with S-mephenytoin
hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics.
5:358–363. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gaikovitch EA, Cascorbi I, Mrozikiewicz
PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN and
Roots I: Polymorphisms of drug-metabolizing enzymes CYP2C9,
CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian
population. Eur J Clin Pharmacol. 59:303–312. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scordo MG, Caputi AP, D'Arrigo C, Fava G
and Spina E: Allele and genotype frequencies of CYP2C9, CYP2C19 and
CYP2D6 in an Italian population. Pharmacol Res. 50:195–200. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bravo-Villalta HV, Yamamoto K, Nakamura K,
Bayá A, Okada Y and Horiuchi R: Genetic polymorphism of CYP2C9 and
CYP2C19 in a Bolivian population: An investigative and comparative
study. Eur J Clin Pharmacol. 61:179–184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Halling J, Petersen MS, Damkier P, Nielsen
F, Grandjean P, Weihe P, Lundgren S, Lundblad MS and Brøsen K:
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese
population. Eur J Clin Pharmacol. 61:491–497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Herrlin K, Massele AY, Jande M, Alm C,
Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson
L and Gustafsson LL: Bantu tanzanians have a decreased capacity to
metabolize omeprazole and mephenytoin in relation to their CYP2C19
genotype. Clin Pharmacol Ther. 64:391–401. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Persson I, Aklillu E, Rodrigues F,
Bertilsson L and Ingelman-Sundberg M: S-mephenytoin hydroxylation
phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics.
6:521–526. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Masimirembwa C, Bertilsson L, Johansson I,
Hasler JA and Ingelman-Sundberg M: Phenotyping and genotyping of
S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona
population of Zimbabwe. Clin Pharmacol Ther. 57:656–661. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kóbori L, Kõhalmy K, Porrogi P, Sárváry E,
Gerlei Z, Fazakas J, Nagy P, Járay J and Monostory K: Drug-induced
liver graft toxicity caused by cytochrome P450 poor metabolism. Br
J Clin Pharmacol. 65:428–436. 2008. View Article : Google Scholar
|
|
30
|
Chen L, Qin S, Xie J, Tang J, Yang L, Shen
W, Zhao X, Du J, He G, Feng G, et al: Genetic polymorphism analysis
of CYP2C19 in Chinese Han populations from different geographic
areas of mainland China. Pharmacogenomics. 9:691–702. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Desta Z, Zhao X, Shin JG and Flockhart DA:
Clinical significance of the cytochrome P450 2C19 genetic
polymorphism. Clin Pharmacokinet. 41:913–958. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Anichavezhi D, Chakradhara Rao US, Shewade
DG, Krishnamoorthy R and Adithan C: Distribution of CYP2C19*17
allele and genotypes in an Indian population. J Clin Pharm Ther.
37:313–318. 2012. View Article : Google Scholar
|
|
33
|
Gurbel PA, Shuldiner AR, Bliden KP, Ryan
K, Pakyz RE and Tantry US: The relation between CYP2C19 genotype
and phenotype in stented patients on maintenance dual antiplatelet
therapy. Am Heart J. 161:598–604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mega JL, Simon T, Collet JP, Anderson JL,
Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P,
Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L,
Sibbing D, Steg PG, Trenk D, Wiviott SD and Sabatine MS:
Reduced-function CYP2C19 genotype and risk of adverse clinical
outcomes among patients treated with clopidogrel predominantly for
PCI: a meta-analysis. JAMA. 304:1821–1830. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Collet JP, Hulot JS, Pena A, Villard E,
Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, et al:
Cytochrome P450 2C19 polymorphism in young patients treated with
clopidogrel after myocardial infarction: A cohort study. Lancet.
373:309–317. 2009. View Article : Google Scholar
|
|
36
|
Ng PC and Henikoff S: Predicting the
effects of amino acid substitutions on protein function. Annu Rev
Genomics Hum Genet. 7:61–80. 2006. View Article : Google Scholar : PubMed/NCBI
|
